Focused on Developing First-in-Class, Targeted Therapies to Reverse the Progression of Rare and Common Forms of Kidney Disease $51M Series A Financing Led by Blue-Chip Investors, ARCH Venture Partners and UCB Ventures Accomplished Team with Proven Track Record in Drug Development Includes Drs. Blaine McKee, President and CEO and Steven Gillis, Chairman Company to Advance Research Pioneered by World-Renowned Renal Disease Investigators and Scientific Co-Founders, Drs.